Ajovy clinical trial shows little improvement over placebo in migraine and depression

Albert Einstein College of Medicine and Teva Pharmaceuticals, in collaboration with multiple international institutions, report findings on the efficacy of fremanezumab (sold as Ajovy by Teva) in reducing migraine frequency and depressive symptoms among patients with comorbid major depressive disorder.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup